A small cancer immunotherapy drug trial in patients with rectal cancer recently had an "unheard of" result: Every single patient treated achieved complete remission.
Why it matters: Based on just 12 patients, the trial was published Sunday in the New England Journal of Medicine and needs to be replicated in a much bigger study. But seeing complete remission in 100% of patients tested is a very promising early signal, researchers said.
